Literature DB >> 19641475

Skin metastases of malignant melanoma: a clinical and prognostic survey.

Paola Savoia1, Paolo Fava, Tiziana Nardò, Simona Osella-Abate, Pietro Quaglino, Maria Grazia Bernengo.   

Abstract

Skin metastases are a frequent event in the natural history of malignant melanoma, both in the early and late phases of disease progression. In this study, we reviewed our database of 4865 melanoma patients, who were diagnosed and followed up prospectively over a 30-year period at our institution. Statistical analyses were focused on patients with secondary involvement of the skin. Seven hundred and thirty-three of the 4030 patients that met the inclusion criteria (18.2%) developed cutaneous metastases; the skin was involved as first site in 413 patients (56.3%) and after regional lymph node spreading in 208 (28.4%) patients. In a lower number of patients, cutaneous metastases developed only in advanced stages of the disease. Skin metastases were mainly locoregional, when arising as the first site of relapse (89.3%) and/or in patients with a primary melanoma of the lower limbs; in contrast, disseminated metastases are more often observed after a visceral involvement and for primary melanomas of the trunk. Moreover, despite a lower disease-free survival rate (1.3 vs. 2.9 years), we showed a significantly longer time to progression to visceral involvement for the group of patients with cutaneous locoregional metastases (62.5 vs. 17.8 months). The site of primary melanoma is strictly related to the pattern of cutaneous recurrence. The disparity in clinical outcome between patients with locoregional or disseminated skin metastases should therefore be taken into consideration in their management.

Entities:  

Mesh:

Year:  2009        PMID: 19641475     DOI: 10.1097/CMR.0b013e32832ac775

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  13 in total

1.  Vitiligo-like hypopigmentation and metastatic melanoma of unknown primary site: friends or foes?

Authors:  Julio Cesar Salas-Alanis; Roger Gonzalez; Giulio Fortuna
Journal:  Med Oncol       Date:  2012-12       Impact factor: 3.064

Review 2.  CT of the skin and subcutaneous tissues.

Authors:  Douglas S Katz; George Ganson; Michelle A Klein; Joseph P Mazzie
Journal:  Emerg Radiol       Date:  2012-09-26

3.  Dermoscopic patterns of melanoma metastases: interobserver consistency and accuracy for metastasis recognition.

Authors:  J Costa; K Ortiz-Ibañez; G Salerni; V Borges; C Carrera; S Puig; J Malvehy
Journal:  Br J Dermatol       Date:  2013-07       Impact factor: 9.302

Review 4.  Cancer microenvironment and genomics: evolution in process.

Authors:  Stanley P Leong; Isaac P Witz; Orit Sagi-Assif; Sivan Izraely; Jonathan Sleeman; Brian Piening; Bernard A Fox; Carlo B Bifulco; Rachel Martini; Lisa Newman; Melissa Davis; Lauren M Sanders; David Haussler; Olena M Vaske; Marlys Witte
Journal:  Clin Exp Metastasis       Date:  2021-05-10       Impact factor: 5.150

5.  Use of neoadjuvant electrochemotherapy to treat a large metastatic lesion of the cheek in a patient with melanoma.

Authors:  Nicola Mozzillo; Corrado Caracò; Stefano Mori; Gianluca Di Monta; Gerardo Botti; Paolo A Ascierto; Corradina Caracò; Luigi Aloj
Journal:  J Transl Med       Date:  2012-06-22       Impact factor: 5.531

6.  TYRP1 mRNA expression in melanoma metastases correlates with clinical outcome.

Authors:  F Journe; H Id Boufker; L Van Kempen; M-D Galibert; M Wiedig; F Salès; A Theunis; D Nonclercq; A Frau; G Laurent; A Awada; G Ghanem
Journal:  Br J Cancer       Date:  2011-11-01       Impact factor: 7.640

Review 7.  HF ultrasound vs PET-CT and telethermography in the diagnosis of In-transit metastases from melanoma: a prospective study and review of the literature.

Authors:  Francesco Maria Solivetti; Flora Desiderio; Antonino Guerrisi; Antonio Bonadies; Carlo Ludovico Maini; Simona Di Filippo; Valerio D'Orazi; Isabella Sperduti; Aldo Di Carlo
Journal:  J Exp Clin Cancer Res       Date:  2014-11-25

8.  Widespread finger skin metastases of melanoma.

Authors:  Faruk Tas; Kayhan Erturk
Journal:  Clin Case Rep       Date:  2018-01-15

9.  Electrochemotherapy by pulsed electromagnetic field treatment (PEMF) in mouse melanoma B16F10 in vivo.

Authors:  Simona Kranjc; Matej Kranjc; Janez Scancar; Jure Jelenc; Gregor Sersa; Damijan Miklavcic
Journal:  Radiol Oncol       Date:  2016-02-16       Impact factor: 2.991

10.  First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma.

Authors:  C Le Tourneau; B Dreno; Y Kirova; J J Grob; T Jouary; C Dutriaux; L Thomas; C Lebbé; L Mortier; P Saiag; M F Avril; E Maubec; P Joly; P Bey; J M Cosset; J S Sun; B Asselain; F Devun; M E Marty; M Dutreix
Journal:  Br J Cancer       Date:  2016-05-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.